George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Warrants

15 May 2020 07:00

RNS Number : 9759M
Motif Bio PLC
15 May 2020
 

 

Motif Bio plc

("Motif Bio" or the "Company")

 

Exercise of Warrants

 

Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, announces that it has received notification from a warrant holder to exercise warrants representing 7,142,857 ordinary shares of 0.01p each ("Ordinary Shares") in the Company for total consideration of £48,571.43. The exercise price of all warrants was 0.68p per warrant.

 

Application has been made for the 7,142,857 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 20 May 2020. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.

 

Following Admission, and further to the announcement made on 5 May 2020, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 654,991,023 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (President and Chief Business Officer)

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0)20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

 

Forward-Looking Statements

When used in this Press Release, the words or phrases "intends," "anticipates," "expected to be" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties including, but not limited to, changes in economic conditions in the Company's market area, changes in policies by regulatory agencies, fluctuations in interest rates, competition that could cause actual results to differ materially from historical earnings and those presently anticipated or projected, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company advises readers that the factors listed above could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revision which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOESFEFMLESSEFI
Date   Source Headline
14th Sep 201611:15 amRNSIssue of Equity
8th Sep 20167:00 amRNSRe-negotiation of the terms of the CPNs
8th Sep 20167:00 amRNSUPDATE ON REVIVE-1 PHASE 3 CLINICAL TRIAL
26th Aug 20167:00 amRNSChief Medical Officer presents at congress in USA
22nd Aug 20164:31 pmRNSDirector/PDMR Shareholding
16th Aug 20167:00 amRNSHalf-year Report
9th Aug 20165:24 pmRNSHolding(s) in Company
9th Aug 20167:00 amRNSUpdate on timing of proposed US Public Offering
5th Aug 20167:00 amRNSHolding(s) in Company
1st Aug 20162:15 pmRNSResult of General Meeting
28th Jul 20164:22 pmRNSPreliminary prospectus filed
18th Jul 20164:38 pmRNSDirector/PDMR Shareholding
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:01 amRNSCircular to allot shares for proposed US Offering
13th Jul 20167:00 amRNSFiles For Proposed U.S. Public Offering
1st Jul 20167:00 amRNSDirectorate Change
2nd Jun 20163:37 pmRNSResult of AGM
1st Jun 20167:00 amRNSCEO to Present at BIO 2016
24th May 20167:00 amRNSInvestor presentation
28th Apr 20167:03 amRNSRe. Amphion Innovations plc
25th Apr 20167:00 amRNSReplay for Analyst & Investor Conference Call
22nd Apr 20167:00 amRNSGrant of Options
21st Apr 20167:00 amRNSAnnual Report and Accounts 2015
20th Apr 20167:00 amRNSFinal Results
18th Apr 20167:00 amRNSResults Conference Call Details
14th Apr 20167:00 amRNSSenior Appointments
23rd Mar 20167:00 amRNSMotif Bio to present at BIO-Europe Spring
14th Mar 20167:00 amRNSAppointment of strategic adviser
2nd Mar 20167:00 amRNSFirst patient dosed in iclaprim Phase 3 trials
23rd Feb 20165:39 pmRNSHolding(s) in Company
22nd Feb 20167:00 amRNSWebcast on Combating antibiotic resistance
25th Jan 20167:00 amRNSAppointments of U.S. finance adviser and auditor
22nd Dec 20157:00 amRNSExercise of Warrants
15th Dec 20157:00 amRNSIclaprim Clinical Trial Supplies Manufactured
7th Dec 20157:00 amRNSMotif selected to present at Biotech Showcase
24th Nov 20157:00 amRNSReceipt of FDA Concurrence
11th Nov 20157:00 amRNSEuropean Agreement for Iclaprim Development
27th Oct 20157:00 amRNSSelected to Present at BIO-Europe 2015
21st Oct 20157:00 amRNSExercise of Options
16th Oct 20157:00 amRNSLeading CRO to Conduct Iclaprim Phase III Trials
13th Oct 20157:00 amRNSResults of Two Posters on Iclaprim at ID Week 2015
12th Oct 20153:59 pmRNSExercise of Options
5th Oct 20154:41 pmRNSDirectors Dealings
29th Sep 20157:01 amRNSPresentation of Two Posters on Iclaprim
23rd Sep 20153:04 pmRNSIssue of Shares for Exercised Warrants
3rd Sep 20157:00 amRNSFDA Grants Fast Track Designation for Iclaprim
2nd Sep 20157:00 amRNSParticipation at Upcoming Investor Events
2nd Sep 20157:00 amRNSAppointment of IR Adviser
27th Aug 20157:01 amRNSInterims Results for the 6 months to 30 June 2015
24th Aug 20157:00 amRNSPotent Efficacy of Iclaprim Confirmed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.